Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

OBJECTIVES: Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying antirhe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavanaugh, Arthur, Mease, Philip J, Gomez-Reino, Juan J, Adebajo, Adewale O, Wollenhaupt, Jürgen, Gladman, Dafna D, Lespessailles, Eric, Hall, Stephen, Hochfeld, Marla, Hu, ChiaChi, Hough, Douglas, Stevens, Randall M, Schett, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033106/
https://www.ncbi.nlm.nih.gov/pubmed/24595547
http://dx.doi.org/10.1136/annrheumdis-2013-205056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033106/
https://www.ncbi.nlm.nih.gov/pubmed/24595547
http://dx.doi.org/10.1136/annrheumdis-2013-205056

Ejemplares similares